These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1649 related articles for article (PubMed ID: 34043894)

  • 1. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.
    Frenck RW; Klein NP; Kitchin N; Gurtman A; Absalon J; Lockhart S; Perez JL; Walter EB; Senders S; Bailey R; Swanson KA; Ma H; Xu X; Koury K; Kalina WV; Cooper D; Jennings T; Brandon DM; Thomas SJ; Türeci Ö; Tresnan DB; Mather S; Dormitzer PR; Şahin U; Jansen KU; Gruber WC;
    N Engl J Med; 2021 Jul; 385(3):239-250. PubMed ID: 34043894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.
    Walsh EE; Frenck RW; Falsey AR; Kitchin N; Absalon J; Gurtman A; Lockhart S; Neuzil K; Mulligan MJ; Bailey R; Swanson KA; Li P; Koury K; Kalina W; Cooper D; Fontes-Garfias C; Shi PY; Türeci Ö; Tompkins KR; Lyke KE; Raabe V; Dormitzer PR; Jansen KU; Şahin U; Gruber WC
    N Engl J Med; 2020 Dec; 383(25):2439-2450. PubMed ID: 33053279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
    Polack FP; Thomas SJ; Kitchin N; Absalon J; Gurtman A; Lockhart S; Perez JL; Pérez Marc G; Moreira ED; Zerbini C; Bailey R; Swanson KA; Roychoudhury S; Koury K; Li P; Kalina WV; Cooper D; Frenck RW; Hammitt LL; Türeci Ö; Nell H; Schaefer A; Ünal S; Tresnan DB; Mather S; Dormitzer PR; Şahin U; Jansen KU; Gruber WC;
    N Engl J Med; 2020 Dec; 383(27):2603-2615. PubMed ID: 33301246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months.
    Thomas SJ; Moreira ED; Kitchin N; Absalon J; Gurtman A; Lockhart S; Perez JL; Pérez Marc G; Polack FP; Zerbini C; Bailey R; Swanson KA; Xu X; Roychoudhury S; Koury K; Bouguermouh S; Kalina WV; Cooper D; Frenck RW; Hammitt LL; Türeci Ö; Nell H; Schaefer A; Ünal S; Yang Q; Liberator P; Tresnan DB; Mather S; Dormitzer PR; Şahin U; Gruber WC; Jansen KU;
    N Engl J Med; 2021 Nov; 385(19):1761-1773. PubMed ID: 34525277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age.
    Muñoz FM; Sher LD; Sabharwal C; Gurtman A; Xu X; Kitchin N; Lockhart S; Riesenberg R; Sexter JM; Czajka H; Paulsen GC; Maldonado Y; Walter EB; Talaat KR; Englund JA; Sarwar UN; Hansen C; Iwamoto M; Webber C; Cunliffe L; Ukkonen B; Martínez SN; Pahud BA; Munjal I; Domachowske JB; Swanson KA; Ma H; Koury K; Mather S; Lu C; Zou J; Xie X; Shi PY; Cooper D; Türeci Ö; Şahin U; Jansen KU; Gruber WC;
    N Engl J Med; 2023 Feb; 388(7):621-634. PubMed ID: 36791162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
    Munro APS; Feng S; Janani L; Cornelius V; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Qureshi E; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kanji N; Libri V; Llewelyn MJ; McGregor AC; Maallah M; Minassian AM; Moore P; Mughal M; Mujadidi YF; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Bawa T; Saralaya D; Sharma S; Sheridan R; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Snape MD; Liu X; Faust SN;
    Lancet Infect Dis; 2022 Aug; 22(8):1131-1141. PubMed ID: 35550261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents.
    Ali K; Berman G; Zhou H; Deng W; Faughnan V; Coronado-Voges M; Ding B; Dooley J; Girard B; Hillebrand W; Pajon R; Miller JM; Leav B; McPhee R
    N Engl J Med; 2021 Dec; 385(24):2241-2251. PubMed ID: 34379915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
    Liu X; Shaw RH; Stuart ASV; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Dinesh T; England A; Faust SN; Ferreira DM; Finn A; Green CA; Hallis B; Heath PT; Hill H; Lambe T; Lazarus R; Libri V; Long F; Mujadidi YF; Plested EL; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Singh N; Turner DPJ; Turner PJ; Walker LL; White R; Nguyen-Van-Tam JS; Snape MD;
    Lancet; 2021 Sep; 398(10303):856-869. PubMed ID: 34370971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial.
    Halperin SA; Ye L; MacKinnon-Cameron D; Smith B; Cahn PE; Ruiz-Palacios GM; Ikram A; Lanas F; Lourdes Guerrero M; Muñoz Navarro SR; Sued O; Lioznov DA; Dzutseva V; Parveen G; Zhu F; Leppan L; Langley JM; Barreto L; Gou J; Zhu T;
    Lancet; 2022 Jan; 399(10321):237-248. PubMed ID: 34953526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.
    Xia S; Zhang Y; Wang Y; Wang H; Yang Y; Gao GF; Tan W; Wu G; Xu M; Lou Z; Huang W; Xu W; Huang B; Wang H; Wang W; Zhang W; Li N; Xie Z; Ding L; You W; Zhao Y; Yang X; Liu Y; Wang Q; Huang L; Yang Y; Xu G; Luo B; Wang W; Liu P; Guo W; Yang X
    Lancet Infect Dis; 2021 Jan; 21(1):39-51. PubMed ID: 33069281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homologous and Heterologous Covid-19 Booster Vaccinations.
    Atmar RL; Lyke KE; Deming ME; Jackson LA; Branche AR; El Sahly HM; Rostad CA; Martin JM; Johnston C; Rupp RE; Mulligan MJ; Brady RC; Frenck RW; Bäcker M; Kottkamp AC; Babu TM; Rajakumar K; Edupuganti S; Dobrzynski D; Coler RN; Posavad CM; Archer JI; Crandon S; Nayak SU; Szydlo D; Zemanek JA; Dominguez Islas CP; Brown ER; Suthar MS; McElrath MJ; McDermott AB; O'Connell SE; Montefiori DC; Eaton A; Neuzil KM; Stephens DS; Roberts PC; Beigel JH;
    N Engl J Med; 2022 Mar; 386(11):1046-1057. PubMed ID: 35081293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age.
    Creech CB; Anderson E; Berthaud V; Yildirim I; Atz AM; Melendez Baez I; Finkelstein D; Pickrell P; Kirstein J; Yut C; Blair R; Clifford RA; Dunn M; Campbell JD; Montefiori DC; Tomassini JE; Zhao X; Deng W; Zhou H; Ramirez Schrempp D; Hautzinger K; Girard B; Slobod K; McPhee R; Pajon R; Das R; Miller JM; Schnyder Ghamloush S;
    N Engl J Med; 2022 May; 386(21):2011-2023. PubMed ID: 35544369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
    Xia S; Duan K; Zhang Y; Zhao D; Zhang H; Xie Z; Li X; Peng C; Zhang Y; Zhang W; Yang Y; Chen W; Gao X; You W; Wang X; Wang Z; Shi Z; Wang Y; Yang X; Zhang L; Huang L; Wang Q; Lu J; Yang Y; Guo J; Zhou W; Wan X; Wu C; Wang W; Huang S; Du J; Meng Z; Pan A; Yuan Z; Shen S; Guo W; Yang X
    JAMA; 2020 Sep; 324(10):951-960. PubMed ID: 32789505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
    Walter EB; Talaat KR; Sabharwal C; Gurtman A; Lockhart S; Paulsen GC; Barnett ED; Muñoz FM; Maldonado Y; Pahud BA; Domachowske JB; Simões EAF; Sarwar UN; Kitchin N; Cunliffe L; Rojo P; Kuchar E; Rämet M; Munjal I; Perez JL; Frenck RW; Lagkadinou E; Swanson KA; Ma H; Xu X; Koury K; Mather S; Belanger TJ; Cooper D; Türeci Ö; Dormitzer PR; Şahin U; Jansen KU; Gruber WC;
    N Engl J Med; 2022 Jan; 386(1):35-46. PubMed ID: 34752019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.
    Sadoff J; Le Gars M; Shukarev G; Heerwegh D; Truyers C; de Groot AM; Stoop J; Tete S; Van Damme W; Leroux-Roels I; Berghmans PJ; Kimmel M; Van Damme P; de Hoon J; Smith W; Stephenson KE; De Rosa SC; Cohen KW; McElrath MJ; Cormier E; Scheper G; Barouch DH; Hendriks J; Struyf F; Douoguih M; Van Hoof J; Schuitemaker H
    N Engl J Med; 2021 May; 384(19):1824-1835. PubMed ID: 33440088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds.
    Usdan L; Patel S; Rodriguez H; Xu X; Lee DY; Finn D; Wyper H; Lowry FS; Mensa FJ; Lu C; Cooper D; Koury K; Anderson AS; Türeci Ö; Şahin U; Swanson KA; Gruber WC; Kitchin N;
    Clin Infect Dis; 2024 May; 78(5):1194-1203. PubMed ID: 38016021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.
    Formica N; Mallory R; Albert G; Robinson M; Plested JS; Cho I; Robertson A; Dubovsky F; Glenn GM;
    PLoS Med; 2021 Oct; 18(10):e1003769. PubMed ID: 34597298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults.
    Haranaka M; Baber J; Ogama Y; Yamaji M; Aizawa M; Kogawara O; Scully I; Lagkadinou E; Türeci Ӧ; Şahin U; Dormitzer PR; Gruber WC; Lockhart S
    Nat Commun; 2021 Dec; 12(1):7105. PubMed ID: 34907170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial.
    Áñez G; Dunkle LM; Gay CL; Kotloff KL; Adelglass JM; Essink B; Campbell JD; Cloney-Clark S; Zhu M; Plested JS; Roychoudhury P; Greninger AL; Patel N; McGarry A; Woo W; Cho I; Glenn GM; Dubovsky F;
    JAMA Netw Open; 2023 Apr; 6(4):e239135. PubMed ID: 37099299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age.
    Anderson EJ; Creech CB; Berthaud V; Piramzadian A; Johnson KA; Zervos M; Garner F; Griffin C; Palanpurwala K; Turner M; Gerber J; Bennett RL; Ali K; Ampajwala M; Berman G; Nayak J; Chronis C; Rizzardi B; Muller WJ; Smith CA; Fuchs G; Hsia D; Tomassini JE; DeLucia D; Reuter C; Kuter B; Zhao X; Deng W; Zhou H; Ramirez Schrempp D; Hautzinger K; Girard B; Slobod K; McPhee R; Pajon R; Aunins A; Das R; Miller JM; Schnyder Ghamloush S;
    N Engl J Med; 2022 Nov; 387(18):1673-1687. PubMed ID: 36260859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 83.